GB201120779D0 - Cancer therapy - Google Patents

Cancer therapy

Info

Publication number
GB201120779D0
GB201120779D0 GBGB1120779.2A GB201120779A GB201120779D0 GB 201120779 D0 GB201120779 D0 GB 201120779D0 GB 201120779 A GB201120779 A GB 201120779A GB 201120779 D0 GB201120779 D0 GB 201120779D0
Authority
GB
United Kingdom
Prior art keywords
therapy
immunomodulator
ultrasound
cancer therapy
embolisation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1120779.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immodulon Therapeutics Ltd
Original Assignee
Immodulon Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immodulon Therapeutics Ltd filed Critical Immodulon Therapeutics Ltd
Priority to GBGB1120779.2A priority Critical patent/GB201120779D0/en
Publication of GB201120779D0 publication Critical patent/GB201120779D0/en
Priority to EP12799260.0A priority patent/EP2785361B1/en
Priority to PCT/GB2012/052992 priority patent/WO2013079980A1/en
Priority to NZ624994A priority patent/NZ624994B2/en
Priority to KR1020147016935A priority patent/KR20140097419A/ko
Priority to BR112014012880A priority patent/BR112014012880A2/pt
Priority to RU2014121335A priority patent/RU2014121335A/ru
Priority to JP2014543984A priority patent/JP6085611B2/ja
Priority to MX2014006511A priority patent/MX2014006511A/es
Priority to CN201280059421.0A priority patent/CN104023733A/zh
Priority to SG11201402396XA priority patent/SG11201402396XA/en
Priority to IN955MUN2014 priority patent/IN2014MN00955A/en
Priority to AU2012343536A priority patent/AU2012343536B2/en
Priority to CA2857429A priority patent/CA2857429A1/en
Priority to US14/361,992 priority patent/US20140356397A1/en
Priority to IL232890A priority patent/IL232890A0/en
Priority to US16/225,028 priority patent/US11318193B2/en
Priority to US16/916,194 priority patent/US11554166B2/en
Priority to US18/154,177 priority patent/US20230149525A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB1120779.2A 2011-12-02 2011-12-02 Cancer therapy Ceased GB201120779D0 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
GBGB1120779.2A GB201120779D0 (en) 2011-12-02 2011-12-02 Cancer therapy
US14/361,992 US20140356397A1 (en) 2011-12-02 2012-12-03 Immunogenic Treatment Of Cancer
MX2014006511A MX2014006511A (es) 2011-12-02 2012-12-03 Tratamiento inmunogénico de cáncer.
SG11201402396XA SG11201402396XA (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer
NZ624994A NZ624994B2 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer
KR1020147016935A KR20140097419A (ko) 2011-12-02 2012-12-03 암의 면역원성 치료
BR112014012880A BR112014012880A2 (pt) 2011-12-02 2012-12-03 tratamento imunogênico do câncer
RU2014121335A RU2014121335A (ru) 2011-12-02 2012-12-03 Иммуногенное лечение рака
JP2014543984A JP6085611B2 (ja) 2011-12-02 2012-12-03 癌免疫療法
EP12799260.0A EP2785361B1 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer
CN201280059421.0A CN104023733A (zh) 2011-12-02 2012-12-03 癌症的免疫原性治疗
PCT/GB2012/052992 WO2013079980A1 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer
IN955MUN2014 IN2014MN00955A (https=) 2011-12-02 2012-12-03
AU2012343536A AU2012343536B2 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer
CA2857429A CA2857429A1 (en) 2011-12-02 2012-12-03 Immunogenic treatment of cancer
IL232890A IL232890A0 (en) 2011-12-02 2014-05-29 Immunogenic therapy for cancer
US16/225,028 US11318193B2 (en) 2011-12-02 2018-12-19 Immunogenic treatment of cancer
US16/916,194 US11554166B2 (en) 2011-12-02 2020-06-30 Immunogenic treatment of cancer
US18/154,177 US20230149525A1 (en) 2011-12-02 2023-01-13 Immunogenic treatment of cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1120779.2A GB201120779D0 (en) 2011-12-02 2011-12-02 Cancer therapy

Publications (1)

Publication Number Publication Date
GB201120779D0 true GB201120779D0 (en) 2012-01-11

Family

ID=45509083

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1120779.2A Ceased GB201120779D0 (en) 2011-12-02 2011-12-02 Cancer therapy

Country Status (15)

Country Link
US (4) US20140356397A1 (https=)
EP (1) EP2785361B1 (https=)
JP (1) JP6085611B2 (https=)
KR (1) KR20140097419A (https=)
CN (1) CN104023733A (https=)
AU (1) AU2012343536B2 (https=)
BR (1) BR112014012880A2 (https=)
CA (1) CA2857429A1 (https=)
GB (1) GB201120779D0 (https=)
IL (1) IL232890A0 (https=)
IN (1) IN2014MN00955A (https=)
MX (1) MX2014006511A (https=)
RU (1) RU2014121335A (https=)
SG (1) SG11201402396XA (https=)
WO (1) WO2013079980A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11963716B2 (en) 2010-07-19 2024-04-23 Emblation Limited Apparatus and method for the treatment of dermatological diseases or conditions
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201308325D0 (en) * 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
WO2015085162A1 (en) 2013-12-05 2015-06-11 Rfemb Holdings, Llc Cancer immunotherapy by radiofrequency electrical membrane breakdown (rf-emb)
EP3043863B1 (en) 2013-09-11 2019-12-04 The Board of Trustees of the Leland Stanford Junior University Arrays of accelerating structures and rapid imaging for facilitating rapid radiation therapies
GB201322725D0 (en) * 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
US11141216B2 (en) 2015-01-30 2021-10-12 Immunsys, Inc. Radio-frequency electrical membrane breakdown for the treatment of high risk and recurrent prostate cancer, unresectable pancreatic cancer, tumors of the breast, melanoma or other skin malignancies, sarcoma, soft tissue tumors, ductal carcinoma, neoplasia, and intra and extra luminal abnormal tissue
RU2733033C2 (ru) * 2015-06-24 2020-09-28 Иммодьюлон Терапьютикс Лимитед Ингибитор контрольных точек и целые клетки микобактерий для применения в терапии рака
RU2596505C1 (ru) * 2015-07-02 2016-09-10 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский радиологический центр" Министерства здравоохранения Российской Федерации (ФГБУ "НМИРЦ" Минздрава России) Способ лечения онкологических больных цитотоксическими лимфоцитами
US10478194B2 (en) 2015-09-23 2019-11-19 Covidien Lp Occlusive devices
KR20180108655A (ko) 2016-01-15 2018-10-04 알에프이엠비 홀딩스, 엘엘씨 암의 면역학적 치료
RU2018136347A (ru) * 2016-04-14 2020-05-14 Фелдрайх Каро Руиз Аб Аппарат для радиационной терапии, включающий модуль ионизации и источник ультрафиолетового света
CA3058380A1 (en) 2017-03-28 2018-10-04 Emblation Limited Stenosis treatment
EP3654976A1 (en) 2017-07-21 2020-05-27 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agents
RU2664597C1 (ru) * 2017-12-12 2018-08-21 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр радиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ радиологии" Минздрава России) Способ комбинированного лечения больных первично операбельным и местно-распространенным неоперабельным раком молочной железы
US20220088231A1 (en) 2018-12-03 2022-03-24 Fusion Pharmaceuticals Inc. Radioimmunoconjugates and dna damage and repair inhibitor combination therapy
EP3918069A1 (en) * 2019-01-31 2021-12-08 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
EP4082577A4 (en) * 2019-12-27 2024-01-03 Zeria Pharmaceutical Co., Ltd. CANCER TREATMENT METHOD AND DRUG
EP4376945A1 (en) * 2021-07-27 2024-06-05 Immodulon Therapeutics Limited A mycobacterium for use in cancer therapy
CN114367060A (zh) * 2022-01-13 2022-04-19 深圳大学 激光交变电场联合治疗仪

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5207223A (en) 1990-10-19 1993-05-04 Accuray, Inc. Apparatus for and method of performing stereotaxic surgery
ATE154759T1 (de) * 1990-11-08 1997-07-15 Univ London Mycobacterium als adjuvans für antigene
US5458125A (en) 1994-01-28 1995-10-17 Board Of Directors Of The Leland Standford Jr. University Treatment planning method and apparatus for radiosurgery and radiation therapy
CA2369542C (en) 1999-04-23 2009-10-27 Qlt Inc. Immuno-adjuvant pdt treatment of metastatic tumors
US20020022032A1 (en) 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
WO2003049751A1 (en) * 2001-12-10 2003-06-19 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CA2492160A1 (en) 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
EP1937303A4 (en) 2005-10-21 2009-11-18 Med College Georgia Res Inst INTRODUCTION OF AN INDOLEAMINE-2,3-DIOXYGENASE IN DENDRITIC CELLS BY TLR LIGANDS AND APPLICATIONS THEREOF
US20080318252A1 (en) 2007-04-23 2008-12-25 Scott Kachlany Rapid assay to test anti-cancer drugs under physiological conditions
GB0526033D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Method
EP2010216A4 (en) * 2006-03-24 2010-06-09 Donald L Morton MYCOBACTERIAL IMMUNOTHERAPY FOR CANCER TREATMENT
WO2008110491A2 (en) 2007-03-09 2008-09-18 University Of Basel Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
US8367075B2 (en) 2010-07-02 2013-02-05 Indian Institute Of Science Synergistic combination and method thereof
EP2683386B1 (en) * 2011-03-09 2017-07-05 The Johns Hopkins University Compounds and methods of use in ablative radiotherapy
WO2012177624A2 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
GB201120779D0 (en) * 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
CA2848985A1 (en) 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
US8617520B2 (en) 2012-02-15 2013-12-31 Immodulon Therapeutics Limited Cancer therapy
GB201308325D0 (en) 2013-05-09 2013-06-19 Immodulon Therapeutics Ltd Cancer Therapy
GB201322725D0 (en) 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
US10835595B2 (en) 2014-01-06 2020-11-17 The Trustees Of The University Of Pennsylvania PD1 and PDL1 antibodies and vaccine combinations and use of same for immunotherapy
US10975112B2 (en) 2015-06-16 2021-04-13 Hangzhou Dac Biotech Co., Ltd. Linkers for conjugation of cell-binding molecules
RU2733033C2 (ru) 2015-06-24 2020-09-28 Иммодьюлон Терапьютикс Лимитед Ингибитор контрольных точек и целые клетки микобактерий для применения в терапии рака
WO2020002905A1 (en) 2018-06-25 2020-01-02 Immodulon Therapeutics Limited Cancer therapy

Also Published As

Publication number Publication date
CA2857429A1 (en) 2013-06-06
WO2013079980A1 (en) 2013-06-06
JP6085611B2 (ja) 2017-02-22
IN2014MN00955A (https=) 2015-04-24
AU2012343536A1 (en) 2014-06-05
IL232890A0 (en) 2014-07-31
US20190224294A1 (en) 2019-07-25
AU2012343536B2 (en) 2017-08-24
NZ624994A (en) 2016-10-28
SG11201402396XA (en) 2014-10-30
EP2785361A1 (en) 2014-10-08
KR20140097419A (ko) 2014-08-06
CN104023733A (zh) 2014-09-03
BR112014012880A2 (pt) 2017-06-13
MX2014006511A (es) 2014-12-05
US11554166B2 (en) 2023-01-17
US20200338181A1 (en) 2020-10-29
US11318193B2 (en) 2022-05-03
RU2014121335A (ru) 2016-01-27
EP2785361B1 (en) 2018-11-28
JP2014533743A (ja) 2014-12-15
US20140356397A1 (en) 2014-12-04
US20230149525A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
MX2014006511A (es) Tratamiento inmunogénico de cáncer.
WO2011137449A3 (en) Method and apparatus for treatment of ocular tissue using combined modalities
US20240123253A1 (en) Photodynamic therapy devices, systems and methods
WO2014153082A3 (en) Systems and methods for treating prostate cancer
JP2014533743A5 (https=)
DK2288413T3 (da) Terapeutisk anlæg, som kombinerer stråleterapi og termoterapi
Yu et al. 18 years long-term results of facial port-wine stain (PWS) after photodynamic therapy (PDT)–A case report
WO2013166504A3 (en) Targeted delivery of active agents using thermally stimulated large increase of perfusion by high intensity focused ultrasound
CN203663257U (zh) 光热和光动力治疗装置
Yanase et al. Hyperthermia enhances the antitumor effect of photodynamic therapy with ALA hexyl ester in a squamous cell carcinoma tumor model
MX2023012091A (es) Dispositivos y sistemas para terapia de ablacion.
Lloyd et al. Laser-tissue interactions
RU2010129236A (ru) Способ лечения местнораспространенных онкологических заболеваний в эксперименте
Jankun A thousand words about the challenges of photodynamic therapy: Challenges of photodynamic therapy
RU2015131129A (ru) Способ фотодинамической терапии фоновых и предраковых заболеваний шейки матки
PH12015502086A1 (en) Ablative immunotherapy
RU2006101260A (ru) Способ фотодинамической терапии онкологических заболеваний
Doornaert et al. Non-coplanar volumetric modulated arc therapy for irradiation of paranasal sinus tumors: In response to Al-Mamgani et al., Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo) radiation. Oral Oncol 2012; 48 (9): 905-11
Soni et al. Spatiotemporal Temperature in a Tumor During Nanorod Assisted Thermal Therapy
LUO et al. Progress on Minimally Invasive Treatment of Localized Prostate Cancer
CA2722001A1 (en) Multi-maser ablation therapy (mmat)
HURWITZ 11.2 Hyperthermia for Prostate Cancer
Lee et al. Use of a 595-nm pulsed-dye laser to treat post-procedure ecchymoses
Kumar et al. Minimally invasive laser therapy for the small and large breast tumours: clinical applications and limitations
Moretti et al. Conventional and unconventional use of lasers in skin disorders

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)